J&J CFO on Orthopedics Spinoff, Earnings, Drug Pricing

Johnson & Johnson's CFO Joe Wolk recently shared insights on the company's promising future, highlighting plans to spin off its slower-growing orthopedics division. With third-quarter sales and earnings surpassing expectations, J&J has also raised its revenue guidance for the year. This strategic move not only positions the company for a strong 2026 but also reflects its commitment to optimizing its business segments and addressing drug pricing concerns, making it a significant development in the healthcare sector.